EA202090165A1 - A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION - Google Patents

A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION

Info

Publication number
EA202090165A1
EA202090165A1 EA202090165A EA202090165A EA202090165A1 EA 202090165 A1 EA202090165 A1 EA 202090165A1 EA 202090165 A EA202090165 A EA 202090165A EA 202090165 A EA202090165 A EA 202090165A EA 202090165 A1 EA202090165 A1 EA 202090165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
losartan
rosuvastatin
diabetes
prevention
Prior art date
Application number
EA202090165A
Other languages
Russian (ru)
Inventor
Чжин А Чон
Хе Юн Бэ
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66174145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA202090165A1 publication Critical patent/EA202090165A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

В изобретении предусмотрены фармацевтическая композиция для предупреждения или лечения сердечно-сосудистого заболевания, сопровождающегося диабетом, и комбинированный препарат, содержащий фармацевтическую композицию. Фармацевтическая композиция содержит амлодипин или его фармацевтически приемлемую соль, лозартан или его фармацевтически приемлемую соль и розувастатин или его фармацевтически приемлемую соль.The invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disease accompanied by diabetes, and a combination preparation containing the pharmaceutical composition. The pharmaceutical composition contains amlodipine or a pharmaceutically acceptable salt thereof, losartan or a pharmaceutically acceptable salt thereof, and rosuvastatin or a pharmaceutically acceptable salt thereof.

EA202090165A 2017-10-17 2018-10-17 A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION EA202090165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170134809 2017-10-17
KR1020180112376A KR20190043076A (en) 2017-10-17 2018-09-19 Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same
PCT/KR2018/012213 WO2019078592A1 (en) 2017-10-17 2018-10-17 Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same

Publications (1)

Publication Number Publication Date
EA202090165A1 true EA202090165A1 (en) 2020-07-10

Family

ID=66174145

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090165A EA202090165A1 (en) 2017-10-17 2018-10-17 A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION

Country Status (12)

Country Link
KR (1) KR20190043076A (en)
CN (1) CN111511369A (en)
CO (1) CO2020001514A2 (en)
CR (1) CR20200096A (en)
EA (1) EA202090165A1 (en)
EC (1) ECSP20014155A (en)
MX (1) MX2020001681A (en)
NI (1) NI202000017A (en)
PH (1) PH12020500295A1 (en)
SG (1) SG11202000622WA (en)
TW (1) TW201922243A (en)
WO (1) WO2019078592A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021251644A1 (en) * 2020-06-09 2021-12-16 한미약품 주식회사 Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100742432B1 (en) 2005-12-27 2007-07-24 한미약품 주식회사 Complex formulation comprising amlodipine camsylate and simvastatin, and method for preparation thereof
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.
MX2009009966A (en) * 2007-03-21 2009-10-07 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance.
KR101181172B1 (en) * 2008-02-22 2012-09-18 한올바이오파마주식회사 Pharmaceutical formulation with chronotherapeutically controlled-release
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR20170003459A (en) * 2015-06-30 2017-01-09 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin

Also Published As

Publication number Publication date
CO2020001514A2 (en) 2020-02-28
CR20200096A (en) 2020-04-03
NI202000017A (en) 2020-03-18
KR20190043076A (en) 2019-04-25
PH12020500295A1 (en) 2020-11-09
ECSP20014155A (en) 2020-04-22
MX2020001681A (en) 2020-07-13
WO2019078592A1 (en) 2019-04-25
SG11202000622WA (en) 2020-02-27
TW201922243A (en) 2019-06-16
CN111511369A (en) 2020-08-07

Similar Documents

Publication Publication Date Title
CY1124084T1 (en) AMIDE SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF
BR112017003054A2 (en) aminopyrimidinyl compounds as jak inhibitors
EA201890654A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS
EA201692436A1 (en) MEDICAL APPLICATION
EA202090688A1 (en) BIS-AMIDE CONNECTIONS ACTIVATING SARCOMER AND VARIANTS OF THEIR APPLICATION
CL2019003078A1 (en) New bicyclic pyrazole derivatives.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
EA201990095A1 (en) CONDENSED THIOPHENE DERIVATIVES ACCEPTABLE AS NAPI-IIb INHIBITORS
EA202190510A1 (en) A NEW DRUG FOR THE TREATMENT OF INFLAMMATORY INTESTINAL DISEASE
EA201491517A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DIHYDROXI-1-METHYL-2-OXO-3-HINOLINKARBOXAMID, ITS PREPARATION AND APPLICATION
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA202090542A1 (en) HIGHLY CONCENTRATED MEDICINAL FORMS OF Pridopidine
EA202190398A1 (en) CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR
WO2017105881A8 (en) Deuterated compounds for treating pain
EA201691796A1 (en) N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE
WO2015001541A3 (en) Pharmaceutical film composition
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EA202090165A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION
EA201891688A1 (en) ADAMANTAN DERIVATIVE AND ITS APPLICATION
MD20180049A2 (en) Pharmaceutical composition
EA201892837A1 (en) PHYSIOLOGICALLY BALANCED COMPOUNDS FOR INJECTIONS, INCLUDING PHOSNET SUPPORTANT